publication date: Nov. 30, 2015
ICT-107 Boosts Overall Survival by 10 Percent In Phase II Glioblastoma Trial
Updated overall survival results and immune response data a phase II trial of ICT-107 in patients with newly diagnosed glioblastoma demonstrated a survival advantage compared to the control group.
ICT-107, developed by ImmunoCellular Therapeutics Ltd., is a dendritic cell-based immunotherapy targeting multiple tumor-associated antigens on glioblastoma stem cells. The study data also show a significant association between immune response and survival, especially in HLA-A2 positive patients, the target patient population for a phase III registration trial.
The data were presented at the annual Scientific Meeting and Education Day of the Society for Neuro-Oncology in San Antonio.
The trial was a randomized, double-blind, placebo-controlled study of the safety and efficacy of ICT-107 in patients with newly diagnosed glioblastoma multiforme following resection and chemoradiation.
ICT-107 is an intradermally administered autologous immunotherapy consisting of the patient’s own dendritic cells pulsed with six synthetic tumor-associated antigens: AIM-2, MAGE-1, TRP-2, gp100, HER-2, IL-13R 2. The placebo control consisted of the patient’s unpulsed dendritic cells. All patients in the trial received standard-of-care temozolomide.
Overall survival results were analyzed at three years after the last patient enrolled. For the 124-patient intent-to-treat population, median OS was 1.6 months or 10 percent better for ICT-107 patients than control. The difference in the Kaplan-Meier survival curves for this patient population was not statistically significant.
Updated OS results for the pre-specified subgroup of HLA-A2+ patients continue to support selecting this patient population alone for a … Continue reading CCL Nov – ICT-107 Boosts Overall Survival by 10 Percent In Phase II Glioblastoma Trial
To access this members-only content, please log in.
Institutional subscribers, please log in with your IP
If you're not a subscriber why not join today?
To gain access to the members only content click here
You will be given immediate access to premium content on the site.Click here to join.